sequeris

Sequeris, also known as Sequeris Therapeutics, is a biopharmaceutical company focused on the development of novel therapies for the treatment of rare diseases. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. Sequeris operates under the principle of "patient-centric" drug development, prioritizing the needs and feedback of patients and their families throughout the research and development process.

The company's pipeline primarily consists of investigational therapies for rare genetic diseases. One of their notable programs is the development of gene editing therapies using CRISPR-Cas9 technology. Sequeris has been involved in the creation of a universal donor CRISPR-Cas9 vector, which aims to reduce the risk of off-target effects and improve the safety and efficacy of gene editing treatments.

Sequeris collaborates with various academic institutions, research organizations, and pharmaceutical companies to advance its drug development efforts. The company has received funding from the National Institutes of Health (NIH) and other sources to support its research initiatives. Sequeris Therapeutics is committed to advancing innovative treatments for rare diseases and improving the lives of patients and their families affected by these conditions.